Error loading player: No playable sources found

Session V: Multispecifics and ADCs Characterization

Date
September 12, 2024
This product is not available for individual purchase, but it is available as part of the following products:

Session Chairs: Chris Chumsae, Bristol-Myers Squibb Company and Frances Namuswe, CDER, FDA


Session Speakers:


Glyco-Analysis of a Glycoengineered VHH-Radioligand Therapy Designed for Improved Biodistribution

David Bush, Novartis 


Characterization of ADCs in Serum and Formulation Buffer

Tun Liu, Johnson & Johnson


Development of Novel Chromatographic and Mass Spectrometric Techniques for Characterizations of BsAbs and ADCs

Fengfei Ma, Merck & Co., Inc.  


Related Products

Thumbnail for Session VII: MS Trends in Regulatory Research, Review, and Standard
Session VII: MS Trends in Regulatory Research, Review, and Standard
Session Chairs: Sarah Rogstad_, CDER, FDA,_ and Frances Namuswe, _CDER, FDA_
Thumbnail for Session VIII: MAM for Product & Process Characterization & Quality Control
Session VIII: MAM for Product & Process Characterization & Quality Control
Session Chairs: Ingo Lindner,_ Roche Diagnostics GmbH_ and Da Ren, _BioTherapeutics Solutions_
Thumbnail for Session II: Mass Spectrometry in Cell & Gene Therapy
Session II: Mass Spectrometry in Cell & Gene Therapy
Session Chairs: : Rich Rogers,_ Umoja Biopharma_ and Chris Yu, _Genentech, __A Member of the Roche Group_